Zoetis (ZTS) Stock Overview
Engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
ZTS Community Fair Values
Create NarrativeSee what 131 others think this stock is worth. Follow their fair value or set your own to get alerts.
Zoetis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$145.94 |
| 52 Week High | US$184.41 |
| 52 Week Low | US$139.34 |
| Beta | 0.90 |
| 1 Month Change | 1.70% |
| 3 Month Change | -3.19% |
| 1 Year Change | -18.93% |
| 3 Year Change | -4.79% |
| 5 Year Change | -7.95% |
| Change since IPO | 370.62% |
Recent News & Updates
Recent updates
Pet Pain For Investor Gain
Sep 26Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?
Jun 30
Zoetis Inc.'s (NYSE:ZTS) Intrinsic Value Is Potentially 41% Above Its Share Price
Apr 30Zoetis Inc. (NYSE:ZTS) Investors Are Less Pessimistic Than Expected
Apr 02Zoetis: Lots Of Growth Opportunities For This High-Quality Compounder
Mar 25Zoetis: Focusing On The High Margin Segments
Mar 13Zoetis Inc. (NYSE:ZTS) Yearly Results: Here's What Analysts Are Forecasting For This Year
Feb 15Zoetis: In-Line Q4 Earnings And Weak Guidance Present A Buying Opportunity
Feb 13Is Zoetis (NYSE:ZTS) Using Too Much Debt?
Jan 31Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 33%?
Jan 10The Wall Street Journal Vs. Zoetis
Dec 26Zoetis: Are Competition And Price Increases A Cause For Concern?
Dec 06Zoetis: Healing Paws, Growing Profits
Nov 29Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy
Nov 18Zoetis: A Solid Choice For The Young Dividend Growth Investor
Oct 09Zoetis: Investing In Pet Health And Portfolio Wealth
Sep 26Zoetis: Librela Sales Should Peak 200-300% Above Management's $1B Target
Aug 13Zoetis Q2 Earnings: Harvesting From DTC (Rating Upgrade)
Aug 07Zoetis: A High-Quality Business And Fast Dividend Growth At A Reasonable Price
Jul 03Zoetis: Don't Fret Excessively Over The Animal Healthcare Leader
Jun 11Zoetis: Why The Focus On Companion Animal Segment Will Pay Off
May 22Zoetis: Long-Term Buy Despite Safety Concerns
May 03Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment
Apr 15Zoetis: My Favorite Healthcare Stock Right Now
Mar 21Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness
Feb 27Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns
Jan 10Shareholder Returns
| ZTS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.3% | 1.3% | 2.0% |
| 1Y | -18.9% | -3.3% | 17.9% |
Return vs Industry: ZTS underperformed the US Pharmaceuticals industry which returned -3.3% over the past year.
Return vs Market: ZTS underperformed the US Market which returned 17.9% over the past year.
Price Volatility
| ZTS volatility | |
|---|---|
| ZTS Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZTS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ZTS's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1950 | 13,800 | Kristin Peck | www.zoetis.com |
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics.
Zoetis Inc. Fundamentals Summary
| ZTS fundamental statistics | |
|---|---|
| Market cap | US$64.68b |
| Earnings (TTM) | US$2.61b |
| Revenue (TTM) | US$9.39b |
Is ZTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZTS income statement (TTM) | |
|---|---|
| Revenue | US$9.39b |
| Cost of Revenue | US$2.68b |
| Gross Profit | US$6.71b |
| Other Expenses | US$4.10b |
| Earnings | US$2.61b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 04, 2025
| Earnings per share (EPS) | 5.89 |
| Gross Margin | 71.50% |
| Net Profit Margin | 27.83% |
| Debt/Equity Ratio | 132.8% |
How did ZTS perform over the long term?
See historical performance and comparisonDividends
Does ZTS pay a reliable dividends?
See ZTS dividend history and benchmarks| Zoetis dividend dates | |
|---|---|
| Ex Dividend Date | Oct 31 2025 |
| Dividend Pay Date | Dec 02 2025 |
| Days until Ex dividend | 4 days |
| Days until Dividend pay date | 36 days |
Does ZTS pay a reliable dividends?
See ZTS dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/26 19:57 |
| End of Day Share Price | 2025/10/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zoetis Inc. is covered by 37 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Douglas Tsao | Barclays |
| Balaji Prasad | Barclays |